Journal
Molecular Neurodegeneration
Publication Date
1-15-2022
Volume
17
Issue
1
First Page
10
Document Type
Open Access Publication
DOI
10.1186/s13024-021-00514-8
Rights and Permissions
Bigley, T.M., Xiong, M., Ali, M. et al. Murine roseolovirus does not accelerate amyloid-β pathology and human roseoloviruses are not over-represented in Alzheimer disease brains. Mol Neurodegeneration 17, 10 (2022). https://doi.org/10.1186/s13024-021-00514-8 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Recommended Citation
Bigley, Tarin M; Xiong, Monica; Ali, Muhammad; Chen, Yun; Wang, Chao; Serrano, Javier Remolina; Eteleeb, Abdallah; Harari, Oscar; Yang, Liping; Patel, Swapneel J; Cruchaga, Carlos; Yokoyama, Wayne M; and Holtzman, David M, "Murine roseolovirus does not accelerate amyloid-β pathology and human roseoloviruses are not over-represented in Alzheimer disease brains." Molecular Neurodegeneration. 17, 1. 10 (2022).
https://digitalcommons.wustl.edu/oa_4/477
Supplementary Fig. 1. Peripheral, neonatal MRV infection in 5XFAD mice does not accelerate Aβ plaque burden.
13024_2021_514_MOESM2_ESM.pdf (795 kB)
Supplementary Fig. 2. Comparisons between MRV purified and unpurified stocks.
13024_2021_514_MOESM3_ESM.pdf (11837 kB)
Supplementary Fig. 3. Effects of acute, intrahippocampal MRV infection on tau pathology.
